Jill P Mesirov
Overview
Explore the profile of Jill P Mesirov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
82678
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ranjbarian T, Antkowiak M, Mallory R, Doherty T, Hosseini M, Mesirov J, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39992648
Introduction: Previous reports have described ETV6-NTRK3 fusion-positive gastrointestinal stromal tumors (GISTs) in cases lacking KIT, PDGFRA, RAS-pathway, or SDHx alterations. However, some investigators have questioned the rigor of these reports...
2.
Garg B, Khan S, Courelli A, Panneerpandian P, Sheik Pran Babu D, Mose E, et al.
Cancer Res
. 2025 Jan;
85(6):1049-1063.
PMID: 39745352
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid cancers; thus, identifying more effective therapies is a major unmet need. In this study, we characterized the super-enhancer (SE) landscape...
3.
Klemm J, Singer D, Mesirov J
Cancer Discov
. 2024 Oct;
14(10):1779-1782.
PMID: 39363746
For more than three decades, concurrent advances in laboratory technologies and computer science have driven the rise of cancer informatics. Today, software tools for cancer research are indispensable to the...
4.
Panda A, Suvakov M, Thorvaldsdottir H, Mesirov J, Robinson J, Abyzov A
Bioinformatics
. 2024 Jul;
40(8).
PMID: 39018173
Summary: Copy number variation (CNV) and alteration (CNA) analysis is a crucial component in many genomic studies and its applications span from basic research to clinic diagnostics and personalized medicine....
5.
Garg B, Khan S, Babu D, Mose E, Gulay K, Sharma S, et al.
bioRxiv
. 2024 Jul;
PMID: 38979336
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid cancers and thus identifying more effective therapies is a major unmet need. In this study we characterized the super enhancer...
6.
Liefeld T, Huang E, Wenzel A, Yoshimoto K, Sharma A, Sicklick J, et al.
J Bioinform Syst Biol
. 2024 Feb;
6(4):379-383.
PMID: 38390437
Non-negative Matrix Factorization (NMF) is an algorithm that can reduce high dimensional datasets of tens of thousands of genes to a handful of metagenes which are biologically easier to interpret....
7.
Gold M, Ong W, Masteller A, Ghasemi D, Galindo J, Park N, et al.
Nat Commun
. 2024 Jan;
15(1):270.
PMID: 38191555
Many genes that drive normal cellular development also contribute to oncogenesis. Medulloblastoma (MB) tumors likely arise from neuronal progenitors in the cerebellum, and we hypothesized that the heterogeneity observed in...
8.
Johnson J, Tsang A, Mitchell J, Zhou D, Bowden J, Davis-Marcisak E, et al.
Nat Protoc
. 2023 Nov;
18(12):3690-3731.
PMID: 37989764
Non-negative matrix factorization (NMF) is an unsupervised learning method well suited to high-throughput biology. However, inferring biological processes from an NMF result still requires additional post hoc statistics and annotation...
9.
Chapman O, Luebeck J, Sridhar S, Wong I, Dixit D, Wang S, et al.
Nat Genet
. 2023 Nov;
55(12):2189-2199.
PMID: 37945900
Circular extrachromosomal DNA (ecDNA) in patient tumors is an important driver of oncogenic gene expression, evolution of drug resistance and poor patient outcomes. Applying computational methods for the detection and...
10.
Castanza A, Recla J, Eby D, Thorvaldsdottir H, Bult C, Mesirov J
Nat Methods
. 2023 Sep;
20(11):1619-1620.
PMID: 37704782
No abstract available.